!!Rafal Dziadziuszko - Publications
\\
__Scientific metrics:__ 184 publications (Scopus), IF: 1095, H-score: 45 (Scopus), 7986 citations (Scopus, viewed on 19/Dec/2021)\\
\\
__Selected publication list:__\\
\\
1. DZIADZIUSZKO Rafal, Krebs Matthew G., de Braud Filippo, Siena Salvatore, Drilon Alexander, Doebele Robert C., Patel Manish R., Cho Byoung Chul, Liu Stephen V., Ahn Myung-Ju, Chiu Chao-Hua, Farago Anna F., Lin Chia-Chi, Karapetis Christos S., Li Yu-Chung, Day Bann-mo, Chen David, Wilson Timothy R., Barlesi Fabrice. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J. Clin. Oncol. 2021: vol. 39, nr 11, pp. 1253-1263. \\
\\
2. DZIADZIUSZKO Rafal, Smith Egbert F., Dafni Urania, Wolf Juergen, Wasag Bartosz, Biernat Wojciech, Finn Stephen P., Kammler Roswitha, Tsourti Zoi, Rabaglio Manuela, Ruepp Barbara, Roschitzki-Voser Heidi, Stahel Rolf A., Felip Enriqueta, Peters Solange. Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J. Thorac. Oncol. 2019 : vol. 14, nr 6, pp. 1086-1094.\\
\\
3. Ceresoli Giovanni L., Aerts Joachim G., DZIADZIUSZKO Rafal, Ramlau Rodryg, Cedres Susana, Van Meerbeeck Jan, Mencoboni Manlio, Planchard David, Chella Antonio, Crinò Lucio, Krzakowski Maciej, Rüssel Jörn, Maconi Antonio, Gianoncelli Luiza, Grosso Federica. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019 : vol. 20, nr 12, pp. 1702-1709.\\
\\
4. McCoach Caroline E., Le Anh T., Gowan Katherine, Jones Kenneth, Schubert Laura, Doak Andrea, Estrada-Bernal Adriana, Davies Kurtis D., Merrick Daniel T., Bunn Paul A., Purcell W. Tom, DZIADZIUSZKO Rafal, Varella-Garcia Marileila, Aisner Dara L., Camidge D. Ross, Doebele Robert C. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. Clin. Cancer Res. 2018: vol. 24, nr 14, pp. 3334-3347.\\
\\
5. Peters Solange, Camidge Ross, Shaw Alice T., Gadgeel Shirish, Ahn Jin S., Kim Dong-Wan, Ou Sai-Hing I., Pérol Maurice, DZIADZIUSZKO Rafal Rosell Rafael, Zeaiter Ali, Mitry Emmanuel, Golding Sophie, Balas Bogdana, Noe Johannes, Morcos Peter N., Mok Tony. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. New Eng. J. Med. 2017: vol. 377, nr 9, pp. 829-838.\\
\\
6. DZIADZIUSZKO Rafal, Le Anh T., Wrona Anna, Jassem Jacek, Camidge Ross, Varella-Garcia Marileila, Aisner Dara L., Doebele Robert C. An activating KIT mutation induces crizotinib resistance in ROS1-positive lung cancer J. Thorac. Oncol. 2016: vol. 11, nr 8, pp. 1273-1281.\\
\\
7. Fehrenbacher Louis, Spira Alexander, Ballinger Marcus, Kowanetz Marcin, Vansteenkiste Johan, Mazieres Julien, Park Keunchil, Smith David, Artal-Cortes Angel, Lewanski Conrad, Braiteh Fadi, Waterkamp Daniel, He Pei, Zou Wei, Chen Daniel S., Yi 111. Jing, Sandler Alan, Rittmeyer Achim, , DZIADZIUSZKO R. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet; 2016: vol. 387, nr 10030, pp. 1837-1846.\\
\\
8. DZIADZIUSZKO Rafal, Baumann Michael, Mitsudomi Tetsuya, Kerr Keith M., Peters Solange, Zimmermann Stefan. Lung cancer; In: Oxford textbook of Oncology; ed. by David J. Kerr, Daniel G. Haller, Cornelis J. H. van de Velde, Michael Baumann, Third edition, Oxford : Oxford University Press, 2016; pp. 628-654.\\
\\
9. Mazières J., Zalcman G., Crinò L., Biondani P., Barlesi F., Filleron T., Dingemans A.-M. C., Léna H., Monnet I., Rothschild S. I., Cappuzzo F., Besse B., Thiberville L., Rouvière D., DZIADZIUSZKO Rafal, Smit E. F., Wolf J., Spirig Ch., Pecuchet N., Leenders F., Heuckmann J. M., Diebold J., Milia J. D., Thomas R. K., Gautschi O. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J. Clin. Oncol. 2015 : vol. 33, nr 9, pp. 992-999.\\
\\
10. Sequist L. V., Soria J.-C., Goldman J. W., Wakelee H. A., Gadgeel S. M., Varga A., Papadimitrakopoulou V., Solomon B. J., Oxnard G. R., DZIADZIUSZKO Rafal, Aisner D. L., Doebele R. C., Galasso C., Garon E. B., Heist R. S., Logan J., Neal J. W., Mendenhall M. A., Nichols S., Piotrowska Z., Wozniak A. J., Raponi M., Karlovich C. A., Jaw-Tsai S., Isaacson J., Despain D., Matheny S. L., Rolfe L., Allen A. R., Camidge D. R. Rociletinib in EGFR-mutated non-small-cell lung cancer. New Eng. J. Med. 2015: vol. 372, nr 18, pp. 1700-1709